Heterogeneity in the pancreatic cancer microenvironment – TGFβ as a master regulator?

Autor: Morton, Jennifer P., Watt, Dale M.

Pancreatic ductal adenocarcinoma is an aggressive disease for which there are very few\ud available therapies. It is notable for its high degree of tumour complexity, with the tumour microenvironment often accounting for the majority of the tumour vo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=core_ac_uk__::b69ea428bfcf107cf42cdd702fd7b659
https://eprints.gla.ac.uk/250259/1/250259.pdf

KRAS Loss of Heterozygosity Promotes MAPK-Dependent Pancreatic Ductal Adenocarcinoma Initiation and Induces Therapeutic Sensitivity to MEK Inhibition.

Autor: Fey SK; CRUK Beatson Institute, Glasgow, United Kingdom., Najumudeen AK; Institute for Molecular Medicine Finland, Helsinki, Finland, Finland., Watt DM; CRUK Scotland Institute, Glasgow, United Kingdom., Millett LM; Cancer Research UK Beatson Institute, United Kingdom., Ford CA; Cancer Research UK Beatson Institute, Glasgow, Scotland, United Kingdom., Gilroy K; Beatson Institute for Cancer Research, Glasgow, United Kingdom., Simpson RJ; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., McLay K; University of Glasgow, Glasgow, East Dunbartonshire, United Kingdom., Upstill-Goddard R; University of Glasgow, Glasgow, United Kingdom., Chang D; University of Glasgow, Glasgow, United Kingdom., Clark W; Beatson Institute for Cancer Research, Glasgow, United Kingdom., Nixon C; CRUK Scotland Institute, Glasgow, United Kingdom., Birch JL; University of Glasgow, Glasgow, East Dunbartonshire, United Kingdom., Barry ST; AstraZeneca (United Kingdom), Cambridge, United Kingdom., Morton JP; CRUK Beatson Institute, Glasgow, United Kingdom., Campbell AD; Cancer Research UK Beatson Institute, Glasgow, United Kingdom., Sansom OJ; CRUK Beatson Institute, Glasgow, United Kingdom.

Publikováno v: Cancer research [Cancer Res] 2024 Oct 16. Date of Electronic Publication: 2024 Oct 16.